Table 2.
ERCC2 Asp312Asn and ERCC2 Lys751Gln polymorphisms and ovarian cancer risk
| Genotype | Cases (%) | Controls (%) | OR (95%CI) | ORadj* (95%CI) | P value |
| ERCC2 Asp312Asn | |||||
| Asp/Asp | 21 (41) | 458 (46) | 1.00 (reference) | 1.00 (reference) | |
| Asp/Asn | 28 (55) | 418 (42) | 1.46 (0.82–2.60) | 0.95 (0.62–1.45) | |
| Asn/Asn | 2 (4) | 118 (12) | 0.37 (0.09–1.51) | 0.9 (0.39–2.12) | 0.088 |
| ERCC2 Lys751Gln | |||||
| Lys/Lys | 1 (2) | 119 (12) | 1.00 (reference) | 1.00 (reference) | |
| Lys/Gln | 31 (61) | 446 (45) | 8.27 (1.54–44.43) | 1.08 (0.70–1.66) | |
| Gln/Gln | 19 (37) | 430 (43) | 5.26 (0.86–32.18) | 1.16 (0.49–2.75) | 0.025 |
* Adjusted for age